Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by The Cleveland Clinic.
Recruitment status was  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
The Cleveland Clinic Identifier:
First received: November 16, 2006
Last updated: December 29, 2010
Last verified: December 2010

RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia in patients with multiple myeloma.

PURPOSE: This clinical trial is studying how well epoetin alfa works in treating anemia in patients undergoing chemotherapy for multiple myeloma.

Condition Intervention
Multiple Myeloma and Plasma Cell Neoplasm
Biological: epoetin alfa

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life

Resource links provided by NLM:

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Efficacy of epoetin alfa as measured by hematologic response and transfusion requirements [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Quality of life as assessed by the Functional Assessment of Cancer Therapy Scales for Anemia (FACT-An) at baseline and at 4, 8, 16, and 24 weeks during treatment [ Time Frame: 24 weeks. ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2005
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: epoetin alfa
    Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
Detailed Description:



  • Determine the efficacy of high-dose epoetin alfa followed by maintenance epoetin alfa in treating moderate anemia, in terms of hematologic response and transfusion requirements, in patients who are undergoing chemotherapy for multiple myeloma.


  • Determine the effect of moderate anemia on quality of life in these patients.
  • Correlate changes in hemoglobin levels with changes in quality of life in patients treated with this drug.
  • Determine the effect of this drug on transfusion requirements after day 28 in these patients.

OUTLINE: This is an open-label, non-randomized, pilot study.

Patients receive high-dose epoetin alfa subcutaneously (SC) once a week for 4 weeks or until their hemoglobin levels reach 12-13 g/dL. Patients then receive epoetin alfa SC once every 2 weeks for 8 weeks OR once a week for 4 weeks, and then once every 2 weeks for 8 weeks (as long as their hemoglobin levels remain between 12-13 g/dL). Patients then receive maintenance epoetin alfa SC once every 4 weeks for up to 12 weeks.

Patients whose hemoglobin level decreases by 1-1.5 g/dL return to previous epoetin alfa schedule. Patients whose hemoglobin level is < 9 g/dL after returning to the previous schedule may receive epoetin alfa for an additional 24 weeks.

Quality of life is assessed at baseline and at weeks 2, 4, 8, 16, and 24 weeks during treatment.

After completion of study treatment, patients are followed periodically for survival.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed multiple myeloma (MM)
  • Requiring active therapy for MM

    • Planning to undergo chemotherapy for ≥ 3 months
  • Moderate anemia caused by MM and/or chemotherapy, as evidenced by hemoglobin ≤ 11.0 g/dL
  • No untreated anemia predominantly due to factors other than MM/chemotherapy (i.e., iron or folate deficiencies, hemolysis, HIV, or gastrointestinal bleeding)


  • ECOG performance status 0-3
  • Life expectancy ≥ 6 months
  • Transferrin saturation ≥ 20%
  • Ferritin ≥ 100 ng/mL
  • Homocysteine normal (concurrent vitamin supplementation allowed)
  • Methylmalonic acid normal (concurrent vitamin supplementation allowed)
  • Renal function normal
  • No uncontrolled hypertension
  • No prior thrombotic events unless treated with appropriate prophylaxis
  • No known hypersensitivity to mammalian cell-derived products
  • No uncontrolled infection
  • No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Weight < 100 Kg
  • Patients with iron, folate, or vitamin B_12 deficiency allowed provided conditions are corrected prior to study entry
  • Able to read and understand English at a 7th grade level


  • See Disease Characteristics
  • No prior total lymphoid, extensive abdominal, or inverted Y radiotherapy
  • Concurrent red blood cell transfusion allowed provided hemoglobin ≤ 7 g/dL AND patient is symptomatic
  • Concurrent vitamin supplementation allowed for cyanocobalamin (vitamin B_12) or folate deficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00400686

United States, Ohio
Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
The Cleveland Clinic
National Cancer Institute (NCI)
Study Chair: Ronald M. Sobecks, MD Case Comprehensive Cancer Center
  More Information

Responsible Party: Ronald Sobecks, Cleveland Clinic Foundation Identifier: NCT00400686     History of Changes
Other Study ID Numbers: CASE-CCF-5497  P30CA043703  ORTHO-CASE-CCF-5497 
Study First Received: November 16, 2006
Last Updated: December 29, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by The Cleveland Clinic:
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
refractory multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Epoetin Alfa
Hematinics processed this record on October 26, 2016